clarithromycin has been researched along with fidaxomicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akeda, Y; Arakawa, Y; Miyamoto, K; Onda, M; Shoji, M; Terada, K; Tomono, K; Tsuchiya, T; Yamabe, K | 1 |
| Huang, H; Jiang, G; Li, H; Liao, X; Sun, Q; Wang, C; Wang, G; Yang, J; Zhao, J | 1 |
2 other study(ies) available for clarithromycin and fidaxomicin
| Article | Year |
|---|---|
Direct anti-biofilm effects of macrolides on Acinetobacter baumannii: comprehensive and comparative demonstration by a simple assay using microtiter plate combined with peg-lid.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Acyl-Butyrolactones; Agrobacterium tumefaciens; Anti-Bacterial Agents; Azithromycin; Biofilms; Biological Assay; Clarithromycin; Erythromycin; Fidaxomicin; Humans; Ivermectin; Josamycin; Microbial Sensitivity Tests; Microbial Viability; Quorum Sensing; Spiramycin | 2020 |
Topics: Anti-Bacterial Agents; Clarithromycin; Clostridioides difficile; Drug Resistance, Bacterial; Fidaxomicin; Humans; Macrolides; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifampin | 2022 |